Skip to main content
CHRS logo

CHRS · Coherus Oncology, Inc. · Analyst Estimates

Track CHRS — free
$0.37 -0.02 (-4.47%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$57.15M
Shares
154.54M
Volume · Nov 20 2.52M Avg daily vol (3M) 1.8M

Analyst Estimates

Compare analyst forecasts for Coherus Oncology, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Pull consensus estimates through the analyst estimates API or MCP →

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians. An EPS figure names its accounting basis, GAAP or Non-GAAP, where the capture records one, and compares only with the company's EPS on that basis; without one, the basis is not recorded.

Captured 2026-11-18 05:06 UTC · Publication dates shown per estimate · 4 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.90
-0.90
-0.90
1
-0.87
-0.86
-0.86
-0.86
0
1
0
1
Revenue
USD
Publication date not stated
56.34M
56.71M
57.04M
5
— — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.62
-0.62
-0.62
1
-0.65
-0.63
-0.63
-0.63
0
0
1
1
Revenue
USD
Publication date not stated
78.02M
87.50M
109.70M
6
— — — — — — — —
Key facts CIK 1512762 CUSIP 19249H103 13F (30d) 150 filings 120 filers Visit website Investor relations